FOLFOX and FOLFIRI Use in Stage IV Colon Cancer: Analysis of SEER-Medicare Data

Overview of attention for article published in Clinical Colorectal Cancer, January 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#11 of 633)
High Attention Score compared to outputs of the same age (93rd percentile)
High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

news: 2 news outlets
policy: 2 policy sources
patent: 4 patents

video: 2 YouTube creators
podcasts: 1 podcast

Readers on

mendeley: 150 Mendeley

So far, Altmetric has seen 2 policy documents that reference this research output.

fruquintinib - Clinical and Pharmacoeconomic Combined Report

Cited by Canadian Agency for Drugs and Technologies in Health (CADTH) on 28 Mar 2024

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency : Final appraisal determination committee papers

Cited by National Institute for Health and Care Excellence (NICE) on 06 May 2021

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

This page shows the most recent policy documents that mention this research output. Click here to find out how to access more activity.